Biomea Fusion, Inc. (BMEA)
NASDAQ: BMEA · IEX Real-Time Price · USD
12.24
-0.54 (-4.23%)
At close: May 17, 2024, 4:00 PM
12.85
+0.61 (4.98%)
After-hours: May 17, 2024, 6:07 PM EDT
Biomea Fusion Market Cap
Biomea Fusion has a market cap or net worth of $440.32 million as of May 17, 2024. Its market cap has decreased by -61.25% in one year.
Market Cap
440.32M
Enterprise Value
306.13M
1-Year Change
-61.25%
Ranking
Category
Stock Price
$12.24
Market Cap Chart
Since the IPO on April 16, 2021, Biomea Fusion's market cap has decreased from $489.05M to $440.32M, a decrease of -9.96%. That is a compound annual growth rate of -3.34%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| May 17, 2024 | 440.00M | -4.22% |
| May 16, 2024 | 459.40M | -3.47% |
| May 15, 2024 | 475.90M | 7.04% |
| May 14, 2024 | 444.60M | 8.02% |
| May 13, 2024 | 411.60M | 7.52% |
| May 10, 2024 | 382.80M | -6.91% |
| May 9, 2024 | 411.20M | 3.34% |
| May 8, 2024 | 397.90M | -7.74% |
| May 7, 2024 | 431.30M | -2.13% |
| May 6, 2024 | 440.70M | -0.72% |
| May 3, 2024 | 443.90M | 3.52% |
| May 2, 2024 | 428.80M | 3.28% |
| May 1, 2024 | 415.20M | 7.70% |
| Apr 30, 2024 | 385.50M | -0.08% |
| Apr 29, 2024 | 385.80M | -0.28% |
| Apr 26, 2024 | 386.90M | 2.95% |
| Apr 25, 2024 | 375.80M | -2.77% |
| Apr 24, 2024 | 386.50M | -1.93% |
| Apr 23, 2024 | 394.10M | 1.39% |
| Apr 22, 2024 | 388.70M | -0.18% |
| Apr 19, 2024 | 389.40M | -2.77% |
| Apr 18, 2024 | 400.50M | -2.96% |
| Apr 17, 2024 | 412.70M | -3.78% |
| Apr 16, 2024 | 428.90M | -4.48% |
| Apr 15, 2024 | 449.00M | -3.61% |
View and export this data all the way back to 2021.
Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| UroGen Pharma | 480.17M |
| Cartesian Therapeutics | 474.27M |
| Clover Health Investments | 471.62M |
| TScan Therapeutics | 471.54M |
| Acelyrin | 468.89M |
| Mereo BioPharma Group | 465.00M |
| Voyager Therapeutics | 464.52M |
| Theravance Biopharma | 464.31M |